Ally Bridge Group’s Taysha Gene Therapies TSHA Stock Holding History

Ally Bridge Group’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-500,000	Closed	-$2.75M	–	31
2025 Q4	$2.75M	Buy	+500,000	New	+$2.43M	2.86%	14

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ally Bridge Group's TSHA Position: Q1 2026 in Review

Ally Bridge Group sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 457,132 shares — an estimated $2.51M sold.

Ally Bridge Group first reported a position in TSHA in Q3 2025 and held it in 2 quarters. The position peaked at $6.21M in Q3 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Ally Bridge Group reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
Ally Bridge Group sold 457,132 Taysha Gene Therapies shares in Q1 2026, an estimated $2.51M.
Ally Bridge Group first reported a position in Taysha Gene Therapies in Q3 2025 and held it in 2 quarters.
Ally Bridge Group's Taysha Gene Therapies position peaked at $6.21M in Q3 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.